TP53 and cancer: The aggregative features of p53 have been monitored for a time by immunohistochemistry (anti-p53 antibodies DO-1 and others) as a surrogate for the identification of tumors carrying p53 mutation [98,103,104,105], which is associated with worsened cancer prognosis (reviewed in [106]).